Eneda Toska, PhD Memorial Sloan Kettering Cancer Center Mutations in the PIK3CA gene are the most frequent genomic alterations in estrogen receptor (ER)-positive breast cancers. One treatment strategy is the use of drugs that inhibit the gene’s signaling pathway—however, many patients eventually become resistant to this type of therapy. Further, PI3K signaling pathway inhibition has […]
Daniel G. Stover, MD Dana-Farber Cancer Institute The host immune system is critical in the control and elimination of tumors in many cancer types. In breast cancer, tumor infiltrating immune cells have been associated with both response to chemotherapy and overall outcome for patients. Understanding what immune cell populations infiltrate tumors may help guide which
Daniel G. Stover, MD Read More »
Mihriban Karaayvaz, PhD Mass General Hospital Cancer Center Making a major impact on the incidence and lethality of breast cancer will require a detailed understanding of the early events in breast cancer development, particularly in women who are at the highest risk of developing these cancers such as those who carry mutations in the BRCA1/2
Mihriban Karaayvaz, PhD Read More »
Jean Albrengues, Ph.D. Ph.D. Cold Spring Harbor Laboratories Dr. Jean Albrengues’ 2016 Terri Brodeur Breast Cancer Foundation fellowship award focuses on the regulation of breast cancer dormancy by the tumor microenvironment. Metastatic breast cancer relapse occurring years after seemingly successful treatment is preceded by an interlude, termed dormancy when cancer remains non-proliferative and undetected at
Jean Albrengues, Ph.D. Read More »
